搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
ENDPOINTS NEWS
4 天
European Commission seeks biopharma feedback on Novo-Catalent deal — re ...
The European Commission is seeking feedback from industry players about Novo Holdings' $16.5 billion proposed acquisition of ...
devdiscourse
4 天
Global Health: Big Pharma Deals, Diabetes Epidemic, and Opioid Cases
It is a fictional representation created for illustrative purposes only. EU antitrust regulators are soliciting feedback from ...
devdiscourse
4 天
Innovations and Challenges in Pharma: A Global Health Report
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
5 天
on MSN
EU regulators see info from rivals, customers in Catalent's sale to Novo Holdings
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...
5 天
on MSN
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
5 天
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
24/7 Wall St
7 天
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
MM&M
12 天
Rx Rundown: Avid Bioservices, Novo Nordisk, Zealand Pharma and more
European Union antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug ...
BioSpace
12 天
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16 ...
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
13 天
Catalent第一季度业绩未达预期,诺和诺德收购交易仍在进行中
周二,合同药品制造商Catalent(纽交所代码:CTLT)公布的第一季度收入未能达到华尔街预期。该公司目前正在被诺和诺德公司旗下的Novo Holdings收购,本季度出现了意外亏损。 Catalent以提供注射器和注射笔的无菌填充和包装服务而闻名,是诺和诺德公司(纽交所代码:NVO)Wegovy减肥药的主要供应商。今年2月,持有诺和诺德公司控股权的Novo Holdings启动了对Catale ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈